» Articles » PMID: 31163301

Establishing a Standard Emotion Processing Battery for Treatment Evaluation in Adults with Autism Spectrum Disorder: Evidence Supporting the Mayer-Salovey-Caruso Emotion Intelligence Test (MSCEIT)

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2019 Jun 5
PMID 31163301
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) and schizophrenia are neurodevelopmental disorders which show markedly similar deficits in emotion processing, yet treatment evaluation in ASD and treatment comparisons across ASD and schizophrenia are constrained by a lack of empirical work validating a standard emotion processing battery across ASD and schizophrenia. Encouragingly, the Mayer-Salovey-Caruso Emotion Intelligence Test, version 2.0 (MSCEIT (Mayer et al., 2003) spans the range of emotion processing deficits in schizophrenia and ASD. This study therefore aimed to establish MSCEIT's factorial, measurement, and structural invariance in community-residing adults with schizophrenia (N = 103) and ASD (N = 113) using multigroup confirmatory factor analysis. Consistent with prior studies in normative populations, a two-factor structure comprised of emotional experiencing and emotional reasoning was supported in ASD and schizophrenia. Both groups operationalize MSCEIT measures similarly, with all measures except for Facilitation and Management showing comparability across groups. To our knowledge, this study is not only the first to establish the measurement and structural invariance of a standard emotion perception battery in adults with ASD, it is also the first to establish its comparability across ASD and schizophrenia. Ultimately, these findings underscore MSCEIT's utility for standardizing treatment evaluation of social cognitive outcomes across the autism-schizophrenia spectrum.

Citing Articles

Methodological issues in social cognition research in autism spectrum disorder and schizophrenia spectrum disorder: a systematic review.

Konstantin G, Nordgaard J, Henriksen M Psychol Med. 2023; 53(8):3281-3292.

PMID: 37161884 PMC: 10277762. DOI: 10.1017/S0033291723001095.

References
1.
Hogarty G, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M . Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004; 61(9):866-76. DOI: 10.1001/archpsyc.61.9.866. View

2.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine D, Quinn K . Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7):748-51. DOI: 10.1176/appi.ajp.2010.09091379. View

3.
Kucharska-Pietura K, Mortimer A . Can antipsychotics improve social cognition in patients with schizophrenia?. CNS Drugs. 2013; 27(5):335-43. PMC: 3657085. DOI: 10.1007/s40263-013-0047-0. View

4.
McCleery A, Lee J, Fiske A, Ghermezi L, Hayata J, Hellemann G . Longitudinal stability of social cognition in schizophrenia: A 5-year follow-up of social perception and emotion processing. Schizophr Res. 2016; 176(2-3):467-472. PMC: 5026923. DOI: 10.1016/j.schres.2016.07.008. View

5.
Nuechterlein K, Green M, Kern R, Baade L, Barch D, Cohen J . The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165(2):203-13. DOI: 10.1176/appi.ajp.2007.07010042. View